abstract: Ritonavir is a powerful inhibitor of the cytochrome P450 3A4 (CYP3A4) isoenzyme. It is used as a pharmaceutical enhancer in the management of HIV-positive patients. However, when co-administered with other drugs that are metabolised via the CYP3A4 pathway, ritonavir can potentially cause serious drug-drug interactions. Inhaled fluticasone propionate, which is used to treat asthma and chronic obstructive airway disease, is particularly prone to such interactions due to its physiological attributes. We report a HIV-positive 48-year-old male patient who presented to Al Nahdha Hospital, Muscat, Oman, in 2012 with weight loss, generalised weakness and fatigue and diagnosed with secondary adrenal insufficiency as a result of concomitant ritonavir and inhaled fluticasone.
‫امل�سابني‬ ‫للمر�سى‬ ‫كعالج‬ ‫ا�ستخدامه‬ ‫يتم‬ ‫والذي‬ .P450 3A4 )CYP3A4( ‫�سيتوكروم‬ ‫أنزمي‬ ‫أيزوا‬ ‫لال‬ ‫قوي‬ ‫مثبط‬ ‫الريتونافري‬ ‫يعترب‬ ‫امللخ�ص:‬ ‫ال�سيتوكروم‬ ‫بها‬ ‫يتحلل‬ ‫التي‬ ‫أي�ص‬ ‫اال‬ ‫عمليات‬ ‫نف�ص‬ ‫طريق‬ ‫عن‬ ‫تتحلل‬ ‫أخرى‬ ‫ا‬ ‫أدوية‬ ‫ا‬ ‫مع‬ ‫ا�ستخدامه‬ ‫عند‬ ‫أنه‬ ‫ا‬ ‫أال‬ ‫ا‬ ‫املكت�سب.‬ ‫املناعي‬ ‫العوز‬ ‫بفريو�ص‬ ‫لعالج‬ ‫ي�ستخدم‬ ‫الذي‬ ‫بروبيونيت،‬ ‫فلوتيكا�سون‬ ‫بخاخ‬ ‫أدوية‬ ‫اال‬ ‫هذه‬ ‫من‬ ‫و‬ ‫الدوائية.‬ ‫التفاعالت‬ ‫هذه‬ ‫نتيجة‬ ‫جانبية‬ ‫ّثار‬ ‫ا‬ ‫حتدث‬
Fluticasone propionate is an inhaled steroid used to manage chronic obstructive airway disease and asthma and is a substrate of the CYP3A4 enzyme similar to beclomethasone, budesonide and triamcinolone. 5 However, fluticasone propionate is more likely to interact with CYP3A4 inhibitors due to its longer half-life, higher glucocorticoid receptorbinding affinity, greater lipophilicity and larger volume distribution. 5 A pharmacokinetic study of healthy volunteers found that ritonavir increased the area under the curve of serum fluticasone by 350-fold. 6 This case report describes the development of secondary adrenal insufficiency in an HIV-positive patient as a result of the concomitant administration of ritonavir and inhaled fluticasone propionate.
T he use of highly-active antiretroviral therapy (HAART) has revolutionised the prognosis of HIV-infected patients and ensured that the infection remains a treatable chronic condition. With prompt diagnosis and treatment, HIVinfected individuals now have a life expectancy similar to that of the general population. 1 Ritonavir, a powerful inhibitor of the cytochrome P 450 3A4 (CYP3A4) isoenzyme, is often prescribed once daily in small doses to HIV patients as a pharmacokinetic enhancer of protease inhibitors. 2 This allows the use of fewer protease inhibitor tablets, hence improving patient compliance and increasing the potency of HAART. 3 However, harmful interactions can occur when ritonavir is co-administered with other drugs that are metabolised via the CYP3A4 pathway, such as corticosteroids, macrolides and statins. 
Case Report
A 48-year-old man presented to the HIV clinic of Al Nahdha Hospital, Muscat, Oman, in 2012 for a routine check-up. He had initially been diagnosed with an asymptomatic HIV infection in 1999 with a baseline cluster of differentiation (CD)4 count of >200 cells/mL 3 . At the time of diagnosis, his only comorbidity was bronchial asthma. Subsequently, the patient had developed an atypical mycobacterial infection in 2008 after which HAART was initiated in the form of 150 mg of lamivudine and 300 mg of zidovudine twice a day and 600 mg of efavirenz once a day. Six months later, due to virological failure, his medication regimen was changed to 400 mg of oral didanosine once a day and 40 mg of oral stavudine and 800/100 mg of oral ritonavir-boosted indinavir/ritonavir twice a day. This resulted in a satisfactory immunological response and complete viral load suppression. However, due to intolerance, these antiretroviral (ARV) drugs were again changed in 2010 to 150 mg of oral lamivudine, 300 mg of oral abacavir and 400/100 mg of oral lopinavir/ritonavir twice a day. From 1999 until 2007, the patient also took 200 μg of inhaled salbutamol as required and 100 μg of inhaled beclomethasone twice a day for his asthma. In 2008, the beclomethasone was substituted for 250 μg of inhaled fluticasone propionate twice a day.
At presentation, the patient reported a twomonth history of weight loss, generalised weakness and fatigue. His vital signs were normal apart from low blood pressure (90/60 mmHg). His examination results were unremarkable, with no signs of Cushing's syndrome or lipodystrophy. Routine investigations, including a complete blood count and urea, electrolyte, liver function, thyroid function and lipid profile tests, were all within normal limits. His CD4 count was 425 cells/mL 3 and the HIV viral load was <20 copies/mL.
At baseline, his morning serum cortisol levels were 7 nmol/L (normal range: 200-550 nmol/L) on two occasions and his plasma adrenocorticotropic hormone (ACTH) level was 5.4 pg/mL (normal range: 7-50 pg/mL). One hour after administrating 250 μg of synthetic ACTH, his cortisol level increased to 71 nmol/L. Levels of other pituitary hormones, plasma sodium and potassium were within normal limits. A diagnosis of secondary adrenal insufficiency was made. The administration of inhaled fluticasone propionate was immediately halted and the patient was instead prescribed 20 mg of oral hydrocortisone in two divided doses per day. Within four weeks, symptoms of weakness and fatigue had dramatically improved; moreover, the asthma symptoms did not worsen and the patient continued using 200 μg of inhaled salbutamol as required. Following the fluticasone withdrawal, basal cortisol levels were 136 nmol/L and 317 nmol/L at 8 and 11 months, respectively. His ACTH level was 43.1 pg/mL at 11 months. After a period of one year, the hydrocortisone dose was tapered successfully over a three month period. Finally, one month after the hydrocortisone was discontinued, the patient's response to synthetic ACTH was normal. Table 1 shows the patient's serial basal and stimulated cortisol levels and plasma ACTH levels over time.
Discussion
Previous research has indicated that the concomitant use of inhaled fluticasone propionate and ritonavir leads to the systemic accumulation of fluticasone, consequently causing iatrogenic Cushing's syndrome and secondary adrenal insufficiency. [7] [8] [9] [10] [11] [12] [13] [14] In a recent literature review, Epperla et al. reported a total of 37 cases of iatrogenic Cushing's syndrome and adrenal suppression as a result of concomitant use of fluticasone and ritonavir in which the time between co-administration and the development of symptoms ranged from two weeks to two years. 7 Another review showed that it took between two weeks and 12 months for patients to experience a complete resolution of symptoms after either drug was discontinued. 8 In the current case, the patient had low ACTH and morning cortisol levels and a subnormal response to synthetic ACTH. This confirmed the diagnosis of secondary adrenal insufficiency. Moreover, the recovery of the hypothalamic-pituitary-adrenal axis after the withdrawal of fluticasone propionate established the cause of the adrenal insufficiency to be a drug-drug interaction.
In the present case, the patient initially reported symptoms of adrenal suppression four years after the concurrent use of fluticasone propionate and ritonavir To the best of the authors' knowledge, this is the first case of secondary adrenal insufficiency as a result of concomitant ritonavir and inhaled fluticasone propionate reported from the Middle East and North African region. The Joint United Nations Programme on HIV/AIDS has advocated for a treatment target of 90% of all HIV-infected people to receive antiretroviral therapy (ART) by 2020; it is therefore likely that the use of ART in this region will increase as the deadline for this target approaches. 16 This expansion of ART provision will require support and vigilance from both pharmacists and HIV physicians in order to avoid serious drug-drug interactions between ART-especially ritonavir-and the medications used to manage other comorbidities. Enhanced communication between HIV clinics and primary healthcare workers is highly recommended to help minimise the frequency of these events. Furthermore, where resources allow, the allocation of an HIVspecialist pharmacist to HIV clinics would ensure that all drug prescriptions are monitored prior to being filled. If this is unfeasible, a more pragmatic approach would be to provide prescribers with a list of common drug-drug interactions and/or access to computerised software to enable drug-drug interaction screening.
Conclusion
This case highlights the potential for serious drugdrug interactions when prescribing a potent CYP3A4 inhibitor (i.e. ritonavir) with other commonly-used
